YOU ARE ABOUT TO LEAVE A GSK WEBSITE

You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for its content.

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user experience, please view this site in a larger browser window.

For US Residents
Select Language
English Español
Prescribing Information Visit US Healthcare Professional Site Visit US HCP Site
USXF DTC Branded with Claims
Tell us what you are looking for in the search box.
SIGN UP TO LEARN MORE
  • About RSV
  • About AREXVY
  • Side Effects
  • Get AREXVY
    • Find AREXVY
    • Cost & Coverage
  • FAQs
  • Sign Up
    • Sign Up to Learn More
    • Sign Up for Reminders
  • Select Language
    • English
    • Español
  • Visit US HCP Site
WHAT IS AREXVY & SAFETY INFO
What Is AREXVY?

What Is AREXVY?

AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older.

Important Safety Information

  • You should not receive AREXVY if you are allergic to any of its ingredients

AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older.

AREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older.

Important Safety Information
Important Safety Information - Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum.
  • You should not receive AREXVY if you are allergic to any of its ingredients
  • A study suggests an increased risk of Guillain-Barré syndrome after vaccination with AREXVY
  • You should not receive AREXVY if you are allergic to any of its ingredients
  • A study suggests an increased risk of Guillain-Barré syndrome after vaccination with AREXVY
  • Fainting can happen after getting injectable vaccines, including AREXVY. Precautions should be taken to avoid injury due to fainting
  • Some people with weakened immune systems may have reduced immune responses to AREXVY
  • The most common side effects are injection site pain, fatigue, muscle pain, headache, and joint pain
  • Vaccination with AREXVY may not result in protection of all vaccine recipients
  • Ask your healthcare provider about the risks and benefits of AREXVY. Only a healthcare provider can decide if AREXVY is right for you

Please see full Prescribing Information.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967. You may also file a report with GSK at gsk.public.reportum.com or 1-888-825-5249.

Resources
GSK Is Here To Help! Contact Us

If you don't have prescription coverage, need cost information, or need help paying for your medicine, visit GSKforyou.com or call 1-866-GSK-FOR-U GSKGSKforyou.com

Utility Links
Legal Notice
Privacy Notice
Consumer Health Privacy
Interest-based Ads
Medicine Savings
Contact Us
Unsubscribe
Follow Us:
FacebookInstagram

Trademarks are owned by or licensed to the GSK group of companies.